-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Jn2PgSVPQyT6aRJ+mYEscI2MnFODMS/3rEsr3tqvJBaRuOTUahdb03RhqaQFwMJA E0VHzFb5dVM7a8a1SLwrEw== 0001104659-05-009772.txt : 20050307 0001104659-05-009772.hdr.sgml : 20050307 20050307162702 ACCESSION NUMBER: 0001104659-05-009772 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20050301 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers FILED AS OF DATE: 20050307 DATE AS OF CHANGE: 20050307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVI BIOPHARMA INC CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: OR FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 05664265 BUSINESS ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: STE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 BUSINESS PHONE: 5032270554 MAIL ADDRESS: STREET 1: ONE SW COLUMBIA STREET 2: SUITE 1105 CITY: PORTLAND STATE: OR ZIP: 97258 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 8-K 1 a05-4635_18k.htm 8-K

 

FORM 8-K

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 1, 2005

 

AVI BioPharma, Inc.

(Exact name of registrant as specified in its charter)

 

Oregon

 

0-22613

 

93-0797222

(State or other jurisdiction of
incorporation or organization)

 

(Commission
File Number)

 

(IRS Employer
Identification Number)

 

 

 

 

 

One S.W. Columbia, Suite 1105
Portland, OR 97258

(Address of principal executive offices)

 

 

 

 

 

(503) 227-0554

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 5.02.              Departure of Directors or Principal officers; election of Directors; Appointment of Principal Officers

 

On March 1, 2005, Raymond Ruddon, M.D., Ph.D., resigned as a member of the Board of Directors.  Dr. Ruddon has been appointed to the Company’s scientific advisory board.

 

On March 4, 2005, K. Michael Forrest was appointed to the Board of Directors to fill the unexpired term of Dr. Ruddon.  Mr. Forrest also was appointed to fill Dr. Ruddon's unexpired term on the Compensation Committee.

 

On March 1, 2005, Patrick L. Iversen, Ph.D., informed the Company that he will not be running for re-election to the Company’s board at the upcoming 2005 Annual Meeting of Shareholders.  He will serve on the board until that meeting.

 

***

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Portland, State of Oregon, on March 7, 2005.

 

 

AVI BioPharma, Inc.

 

 

 

 

 

By:

/s/ ALAN P. TIMMINS

 

 

 

 

 

 

 

 

Alan P. Timmins

 

 

 

President and Chief Operating Officer
(Principal Operating Officer)

 

 

2

 -----END PRIVACY-ENHANCED MESSAGE-----